Lenalidomide Krka (lenalidomide) Pregnancy Reporting Form

This Pregnancy Reporting Form must be completed for each female patient or female partner of a male patient who experienced pregnancy during therapy with lenalidomide.

Pregnancy Reporting Form must be sent to KRKA, d.d., Novo mesto IMMEDIATELY. Please see contact details below.

 $Krka, d.d., Novo\ mesto\ may\ contact\ you\ in\ orde\underline{\ \ }\ to\ gather\ additional\ information\ regarding\ foetal\ exposure\ to\ lenalidomide.$

KRKA, d.d., Novo mesto
Telephone : +353 1 413 3710
Email⊠: pharmacovigilance.IE@krka.biz

Reporter's Information									
Reporter's Name:				Reporter's Profession:					
Telephone number:				Email:					
Address:				Data of accounts	DD MM	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\			
Address:				Date of awarenes	SS: DD IVIIVI	YYYY			
Patient and therapy Information				-					
Pregnant Woman's Initials (patient or f	female part	ner of a male	patient re	ceiving Date of Birth: DD MM YYYY Age:					
lenalidomide):									
Please select one of the options below	:	_							
☐ Pregnancy of Patient				of Patient's		Exposure of a Pr	egnant Female		
		Р	artner						
Drug Name:									
Batch Number:	Shelf life:			Daily dosage:		Frequency:			
24.6.1.1.4.1.1.5.1.1	onen me			July Goodge.		rrequericy.			
Date of First Dose: DD MM YYYY				Date of Last Dose: DD MM YYYY					
Indication:									
mulcation.									
Pregnancy test		Reference R	ange:	Date DD			MM YYYY		
☐ Urine Qualitative									
☐ Serum Quantitative									
Date of Last Menstrual Period:									
Female is Currently: weeks pregnant No			No Longer Pregnant			Unknown			
						<u> </u>			
Female has elected to		Carry	Carry Pregnancy to Term			Estimated Delivery Date: DD MM YYYY			
		Termi	Terminate Pregnancy			Date Performed or Pending: DD MM YYYY			
Patient's Prescriber's Information:									
Prescriber Name:		Date: DD MM YY	YY						
Tresenser rune.									
Address:				Email:					
Address.									
Phone number:				Fax:					
Name of the nerson completing this for	orm		Signat	ure		D.	ate DD MM VVVV		
Name of the person completing this fo	orm		Signat	ure		Da	ate DD MM YYYY		
Name of the person completing this fo	orm		Signat	ure		Da	ate DD MM YYYY		
Name of the person completing this fo	orm		Signat	ure		Da	ate DD MM YYYY		

Background Information on Reason for Pregnancy										
Was patient erroneous	Was patient erroneously considered not to be of childbearing potential?									NO
	reason for considering not to be of childbearing potential									
 Age ≥ 50 years and naturally amenorrhoeic* for ≥ 1 year *amenorrhoea following cancer therapy or during breast-feeding does not rule out childbearing potential 										NO
			YES		NO					
	ovarian failure confirmed by a specialist gynaecologist ateral salpingo-oophorectomy, or hysterectomy									NO NO
	ner syndrome, uterine ag							YES YES		NO
	elow what contraception									
 Implant 		YES		NO						
 Levonorgestrel-re 		YES YES		NO						
 Medroxyprogesterone acetate depot Tubal sterilisation (specify below) 										NO NO
	igation							YES YES		NO
	diathermy							YES		NO
o Tubal chips										NO
Sexual intercourse	e with a vasectomised ma	le partner only; vasecto	my must b	e confirmed	l by two nega	ative semen analyses		YES		NO
 Ovulation inhibite 	ory progesterone-only pill	s (i.e. desogestrel)						YES		NO
Other progestero								YES		NO
Combined oral co Other intra utering								YES YES		NO NO
Other intra-uterinCondoms	ie devices							YES		NO
Cervical cap								YES		NO
 Sponge 								YES		NO
 Withdrawal 								YES		NO
Other								YES		NO
None Indicate from the list b	alaw the vesser for sout	wasanting failura						YES		NO
	Indicate from the list below the reason for contraceptive failure Missed oral contraception									NO
	or intercurrent illness in	teracting with oral cont	traception					YES		NO
	with barrier method	- U	'					YES		NO
 Unknown 								YES YES		NO
Had the patient committed to complete and continuous abstinence										NO
	ted despite patient alrea			-14				YES		NO
Did patient receive educational materials on the potential risk of teratogenicity Did patient receive instructions on pood to avoid programmy. Did patient receive instructions on pood to avoid programmy.								YES		NO NO
·										
Prenatal Information Date of Last Menstrual	Pariod: DD MM VVVV			Ectimato	d Dolivory D	ate: DD MM YYYY				
Pregnancy test	Period. DD WIWI 1111			Estillate	u Delivery D	ate. DD WIWI TTTT				
☐ Urine	Reference Range:			Da	te: DD MM '	YYYY				
Qualitative	Defended Borner									
☐ Serum Reference Range: Date: DD MM YYYY Quantitative										
Past Obstetric History										
Year of Pregnancy	Outcome					Gestational Age		Type of	Delive	ery
YYYY	☐ Spontaneous	☐ Therapeutic	☐ Liv	ve 🗆	Still birth					
	abortion	abortion	I	rth						
YYYY	☐ Spontaneous	☐ Therapeutic	I	ve 🗆	Still birth					
YYYY	abortion Spontaneous	abortion Therapeutic		rth ve \Box	Still birth	+	\dashv			
	abortion	abortion		rth	Juli bir ur					
YYYY	☐ Spontaneous	☐ Therapeutic	☐ Liv	ve 🗆	Still birth					
V V V V	abortion	abortion		rth	C#:III Jeresal	-	\rightarrow			
YYYY	☐ Spontaneous abortion	☐ Therapeutic abortion		ve 🗆	Still birth					
Diubb defeate	asortion	33010011	51							
Birth defects Was there any birth de	fect from any pregnancy	?				YES 🗆 NO		UNKN	OWN	
	ory of any congenital ab					YES NO		UNKN		
If yes to either of these	questions, please provi	de details below:								
Maternal Past Medical History										
Condition	From Date	To Date	Т	reatment		Outcome				
	DD MM YY					2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2				
	DD MM YY	YY DD MM YYYY								
	DD MM YY									
	DD MM YY									
	DD MM AY	VVV DD MM VVVV								

ason for Pregnancy ditions						
From Date		Treatment				
DD MM YYYY						
DD MM YYYY						
DD MM YYYY						
DD MM YYYY						
DD MM YYYY						
DD MM YYYY						
DD MM YYYY						
DD MM YYYY						
☐ YES	□ NO	If yes, amount/units per day:				
☐ YES	□ NO	If yes, amount per day:				
☐ YES	□ NO	If yes, provide details:				
od over the counter m	Stop date/	pplements) Indication				
	Continuing					
DD MM YYYY	DD MM YYYY					
DD MM YYYY	DD MM YYYY					
DD MM YYYY	DD MM YYYY					
DD MM YYYY	DD MM YYYY					
DD MM YYYY	DD MM YYYY					
DD MM YYYY	DD MM YYYY					
is form	Signature	D	Date DD MM YYYY			
	DD MM YYYY	From Date DD MM YYYY	From Date DD MM YYYY DD MM Y			

Your personal data (aggregated anonymised patient limited data e.g., patient initials, date of birth) will be processed by KRKA d.d. Novo mesto, as Marketing Authorisation Holder (MAH) of pharmaceutical products and its worldwide affiliates, to the extent and for as long as necessary, for the purposes of the compliance with drug safety legal obligations and for storage purposes.

To conduct risk management program activities, we may use third party service providers, who will handle directly any reporting relating to pregnancy, acting on our behalf, and upon our prior instructions.

KRKA may disclose your personal information to regulatory authorities, affiliates of the KRKA Group, service providers or other collaborators. Some of these entities may be located outside of the EU. KRKA will take appropriate measures, such as implementing standard data protection clauses adopted by the European Commission, to ensure that your personal information will be kept secure in accordance with applicable data protection law. KRKA will only retain your personal data for the length of time required by law.

Under applicable law, you may have the right to access and verify your personal information held by KRKA, receive a copy of it, obtain its correction and deletion if it is inaccurate and object to certain processing. If you wish to exercise those rights, you can contact our data protection officer at Info.IE@krka.biz

Reporter's Signature (required)	Date DD MM YYYY

On behalf of KRKA, thank you for providing information that will assist us in our commitment to patient safety.

Event-Specific Questionnaire for HCP – Pregnancy Outcome Form

This form must be returned to KRKA, d.d., Novo mesto; Telephone 1: +353 1 413 3710; Email⊠: pharmacovigilance.IE@krka.biz

Reporter's Information									
Reporter's Name:						Email:			
Reporter's Profession:						Telephone number:			
Address:						Fax number:			
Patients Information									
Patient's ID:	Date	e of birth:	DD N	1M YYYY			Ethnicity:		
					□ V	Vhite	☐ African-Caribbean	☐ Other, specify:	
Partners of patients Information	-						<u> </u>	-	
☐ Not applicable Ethinicity:					□ V	Vhite	☐ African-Caribbean	☐ Other, specify:	
Pregnancy Outcome		<u> </u>			<u>"</u>		- 1	-	
Date of delivery:	DD	MM YYYY					Gestation age of delivery:	DD MM YYYY	
Normal		No		Yes			The second of th		
C-section		No		Yes					
Induced		No		Yes					
Ectopic pregnancy		No		Yes					
Elective termination		No		Yes	Date:	DD MM Y	YYY		
Spontaneous abortion (≤20 weeks)	111			Yes	Weeks from LMP:				
Foetal death/stillbirth (>20 weeks)		No		Yes					
Were the products of conception examined?		No		Yes	If yes, was the foetus normal? If no describe below/Unknown				
					, ,,			,	
Obstetrics Information					1				
Complications during pregnancy		No		Yes	If yes,	please sp	ecify:		
Complications during labour/delivery		No		Yes	If yes, please specify:				
Post-partum maternal complications		No		Yes	If yes,	please sp	ecify:		
Foetal Outcome									
Live normal infant		No		Yes					
Foetal distress		No		Yes					
Intra-uterine growth retardation		No		Yes					
Neonatal complication		No		Yes	If yes,	please spe	ecify:		
Birth defect noted?		No		Yes	If yes,	please spe	ecify:		
Sex		Male		Female					
					Birth v	veight:	lbsoz orKg		
						- 0	0		
					Length	in	nchs orcm		
	-		<u> </u>	10 :					
Apgar score	1 m	ın: 5 n	nın:	10 min:	🗆	Unkno	wn		
Signature of the person completing this for	orm (ı	required)				Date DD MM YYYY		
and the same to the same to the same to	· · · · · · · ·		,						
Data Privacy Notice									

Your personal data (aggregated anonymised patient limited data e.g., patient initials, date of birth) will be processed by KRKA d.d. Novo mesto, as Marketing Authorisation Holder (MAH) of pharmaceutical products and its worldwide affiliates, to the extent and for as long as necessary, for the purposes of the compliance with drug safety legal obligations and for storage purposes.

To conduct risk management program activities, we may use third party service providers, who will handle directly any reporting relating to pregnancy, acting on our behalf, and upon our prior instructions.

KRKA may disclose your personal information to regulatory authorities, affiliates of the KRKA Group, service providers or other collaborators. Some of these entities may be located outside of the EU. KRKA will take appropriate measures, such as implementing standard data protection clauses adopted by the European Commission, to ensure that your personal information will be kept secure in accordance with applicable data protection law. KRKA will only retain your personal data for the length of time required by law.

Under applicable law, you may have the right to access and verify your personal information held by KRKA, receive a copy of it, obtain its correction and deletion if it is inaccurate and object to certain processing. If you wish to exercise those rights, you can contact our data protection officer at Info.IE@krka.biz

Reporter's Signature (required)	Date DD MM YYYY

On behalf of KRKA, thank you for providing information that will assist us in our commitment to patient safety.